EGFRvIII antibody and composition comprising same

Abstract

The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.

What is claimed is: 
     
       1. An antibody binding to epidermal growth factor receptor variant III (EGFRvIII) comprising an amino acid sequence of SEQ ID NO: 1, wherein the antibody comprises the following heavy chain variable region and light chain variable region selected from the group consisting of:
 a heavy chain variable region comprising the sequence of SEQ ID NO: 28 and a light chain variable region comprising the sequence selected from the group consisting of SEQ ID NOS: 32-35; 
 a heavy chain variable region comprising the sequence of SEQ ID NO: 29 and a light chain variable region comprising the sequence of SEQ ID NO: 33; 
 a heavy chain variable region comprising the sequence of SEQ ID NO: 30 and a light chain variable region comprising the sequence of SEQ ID NO: 34; and 
 a heavy chain variable region comprising the sequence of SEQ ID NO: 31 and a light chain variable region comprising the sequence of SEQ ID NO: 35. 
 
     
     
       2. A human antibody binding to epidermal growth factor receptor variant III (EGFRvIII) comprising an amino acid sequence of SEQ ID NO: 1, wherein the antibody comprises the following heavy chain variable region and light chain variable region selected from the group consisting of:
 a heavy chain variable region comprising the sequence of SEQ ID NO: 28 and a light chain variable region comprising the sequence selected from the group consisting of SEQ ID NOS: 32-35; 
 a heavy chain variable region comprising the sequence of SEQ ID NO: 29 and a light chain variable region comprising the sequence of SEQ ID NO: 33; 
 a heavy chain variable region comprising the sequence of SEQ ID NO: 30 and a light chain variable region comprising the sequence of SEQ ID NO: 34; and 
 a heavy chain variable region comprising the sequence of SEQ ID NO: 31 and a light chain variable region comprising the sequence of SEQ ID NO: 35. 
 
     
     
       3. A pharmaceutical composition for treating a cancer or a tumor comprising the antibody according to  claim 1  or  2  as an active ingredient. 
     
     
       4. A nucleic acid encoding the antibody according to  claim 1 . 
     
     
       5. The nucleic acid according to  claim 4 , comprising at least one sequence encoding a heavy chain variable region and selected from the group consisting of SEQ ID NOS: 36-39. 
     
     
       6. The nucleic acid according to  claim 4 , comprising at least one sequence encoding a light chain variable region and selected from the group consisting of SEQ ID NOS: 40-43. 
     
     
       7. A vector comprising the nucleic acid according to  claim 4 . 
     
     
       8. A cultured host cell comprising the vector according to  claim 7 . 
     
     
       9. A method of producing an antibody binding to epidermal growth factor receptor variant III (EGFRvIII) comprising an amino acid sequence of SEQ ID NO:1, comprising culturing the host cell of  claim 8  for a period of time sufficient to express the antibody by the host cell, and separating and/or purifying the expressed antibody.